SURVIVAL ANALYSIS OF COVID-19 PATIENTS FOLLOWING HEMODIALYSIS INITIATION AT M. DJAMIL HOSPITAL, PADANG, WEST SUMATRA

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/a3f7f19294eec2bb1b52796db3c89433.pdf

Abstract Title *

SURVIVAL ANALYSIS OF COVID-19 PATIENTS FOLLOWING HEMODIALYSIS INITIATION AT M. DJAMIL HOSPITAL, PADANG, WEST SUMATRA

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Deka Viotra Kamaruddin decaviotra@gmail.com Andalas University Internal Medicine Padang Indonesia -

Co-author 2

Shayna Amala Rashieka shaynaa.rashieka@gmail.com Andalas University General Practitioner Padang Indonesia *

Co-author 3

Fauzar Fauzar drfauzar@yahoo.com Andalas University Internal Medicine Padang Indonesia -

Co-author 4

Roza Kurniati dr_rozakurniati@yahoo.com Andalas University Internal Medicine Padang Indonesia -

Co-author 5

Devia Putri Lenggogeni deviaputri@nrs.unand.ac.id Andalas University Medical Surgical Nursing Padang Indonesia -

Co-author 6

Shaydi Amala Rashieka shaydiamalar@gmail.com Andalas University General Practitioner Padang Indonesia -

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Coronavirus disease 2019 (COVID-19) has affected millions globally, with kidney involvement commonly presenting as acute kidney injury (AKI) or acute-on-chronic kidney disease. Hemodialysis is a key treatment for AKI. This study aimed to describe the survival rate of COVID-19 patients undergoing hemodialysis initiation.

Methods

A retrospective study was conducted from January 2021 to February 2022 at Dr. M. Djamil General Hospital, Padang, Indonesia. Data from medical records of COVID-19 patients with AKI were analyzed for demographics, laboratory parameters, and survival outcomes.

Results

Fifty-seven patients were included; 39 (68.4%) had severe COVID-19. The mean age was 59.25 years. Twenty patients (35.1%) survived, and 37 (64.9%) died with an average hospital stay of 12 days. Significant differences before and after hemodialysis were observed in hemoglobin, leukocyte, thrombocyte, urea, sodium, pCO₂, PT, APTT, and globulin (p<0.05). COVID-19 severity was the only factor significantly affecting survival (AOR 52.846; 95% CI: 6.267–421.381; p<0.001). Kaplan–Meier analysis showed longer survival in moderate cases (19.7 vs. 11.3 days; p<0.001).

Conclusion

Renal involvement in COVID-19 remains a major challenge. The survival of hemodialysis-initiated patients depends primarily on disease severity, with moderate cases showing better outcomes.

Kewords